Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $26.6667.

Several research firms recently commented on NBTX. UBS Group raised their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Guggenheim raised their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Monday.

Nanobiotix Trading Down 3.9%

Shares of NBTX stock opened at $49.48 on Tuesday. Nanobiotix has a 1-year low of $3.64 and a 1-year high of $57.14. The firm’s 50-day simple moving average is $35.36 and its 200-day simple moving average is $27.04.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million for the quarter. On average, equities research analysts forecast that Nanobiotix will post 0.53 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NBTX. Optiver Holding B.V. purchased a new stake in shares of Nanobiotix during the third quarter valued at approximately $101,000. Marshall Wace LLP purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $220,000. Royal Bank of Canada raised its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.